New Zealand markets close in 5 hours 34 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
683.44-7.44 (-1.08%)
At close: 04:00PM EDT
683.50 +0.06 (+0.01%)
After hours: 07:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close690.88
Bid670.07 x 800
Ask695.53 x 800
Day's range682.90 - 697.01
52-week range492.13 - 747.42
Avg. volume646,066
Market cap75.073B
Beta (5Y monthly)0.24
PE ratio (TTM)9.72
EPS (TTM)70.31
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est703.14
  • Motley Fool

    Why Regeneron Investors Shouldn't Fear Its Patent Cliff

    Biotechnology giant Regeneron's (NASDAQ: REGN) eye medication EYLEA is one of the best-selling blockbuster drugs around, generating $9.4 billion sales globally in 2021. The drug is approved for a number of eye diseases and has been a mainstay for Regeneron for the past decade. Although its patents are nearing the end of their lifespan, Regeneron has a number of new treatments that will step in to replace lost revenue.

  • Zacks

    SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

    SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

  • Zacks

    Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

    Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.